Novartis Gains 58% PSA Progression Risk Reduction with Pluvicto in Hormone-Sensitive Prostate Cancer

Simultaneous regulatory submissions in the US, China and Japan place Novartis's radioligand therapy Pluvicto® (lutetium [177Lu] vipivotide tetraxetan) at a critical CMC and supply-chain inflection point, with decisions expected in H2 2026 across all three markets. New PSMAddition data presented at the American Urological Association Annual Meeting 2026 now add clinical weight to those filings.

The second interim analysis of PSMAddition showed a 58% lower risk of PSA progression (HR 0.42; 95% CI: 0.30–0.59) in PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC) patients receiving Pluvicto combined with standard of care, androgen receptor pathway inhibitor plus androgen deprivation therapy, versus standard of care alone. Deep PSA reduction, defined as a nadir below 0.2 ng/mL, was consistently higher in the Pluvicto arm at every measured interval: 47.6% vs. 37.7% at Week 12, 73.7% vs. 59.7% at Week 24, and 87.4% vs. 74.9% at Week 48.

For QA directors and regulatory leads tracking the sNDA dossiers, the safety data carry equal weight. Grade ≥3 adverse events were reported in 50.7% of patients in the Pluvicto-plus-SoC arm versus 43% on SoC alone. The tolerability profile was described as consistent with prior VISION and PSMAfore data, a characterization that will inform labeling negotiations across jurisdictions with differing post-market surveillance requirements.

The manufacturing dimension of a three-market approval cycle for an RLT product is non-trivial. Lutetium-177 carries a physical half-life of approximately 6.7 days, compressing the window between batch release and patient administration and demanding specialized GMP infrastructure, hot-cell suites, qualified radiopharmacy networks, and validated cold-chain logistics, at a scale that standard small-molecule or biologic facilities cannot accommodate. Regulatory CMC packages filed under 21 CFR Part 211 in the US, and equivalent frameworks in China and Japan, will need to demonstrate process validation across that constrained logistics envelope.

Approximately 186,000 men are diagnosed with mHSPC annually across the eight markets covered by the sNDA submissions. Progression to metastatic castration-resistant prostate cancer typically occurs within 20 months of diagnosis and carries a life expectancy below two years, framing the commercial and supply urgency that plant heads will need to translate into validated capacity plans before first approvals land.

The measurable checkpoint for operations and regulatory teams is the H2 2026 decision window, against which batch-record readiness, site qualification, and distribution network validation will need to be aligned.

Source: Novartis via GlobeNewswire, 17 May 2026.